## Clément Larrue

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/396196/publications.pdf

Version: 2024-02-01

33

all docs

28 2,097 21 papers citations h-index

33

docs citations

h-index g-index

33 3641
times ranked citing authors

27

| #  | Article  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discovery, 2017, 7, 716-735.   | 9.4  | 582       |
| 2  | Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood, 2015, 126, 1346-1356.  | 1.4  | 303       |
| 3  | Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood, 2016, 127, 882-892.   | 1.4  | 108       |
| 4  | Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. Nature Communications, 2020, 11, 4056.   | 12.8 | 96        |
| 5  | APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica, 2022, 107, 403-416.  | 3.5  | 95        |
| 6  | Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nature Communications, 2017, 8, 1903.   | 12.8 | 84        |
| 7  | Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia. Oncogene, 2018, 37, 787-797.   | 5.9  | 82        |
| 8  | CHK1 as a therapeutic target to bypass chemoresistance in AML. Science Signaling, 2016, 9, ra90.   | 3.6  | 73        |
| 9  | A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Blood Cancer Journal, 2015, 5, e297-e297.   | 6.2  | 68        |
| 10 | Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 483-497.  | 8.5  | 68        |
| 11 | Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 131-142.                          | 2.2  | 57        |
| 12 | Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.<br>Journal of Experimental Medicine, 2021, 218, .   | 8.5  | 56        |
| 13 | Antileukemic Activity of 2-Deoxy- <scp>d</scp> -Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with <i>FLT3-ITD</i> or <i>c-KIT</i> Mutations. Molecular Cancer Therapeutics, 2015, 14, 2364-2373. | 4.1  | 52        |
| 14 | Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica, 2018, 103, 988-998.  | 3.5  | 49        |
| 15 | Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine<br>Resistance in Human Acute Myeloid Leukemia. Cancer Research, 2019, 79, 5191-5203.   | 0.9  | 45        |
| 16 | Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1204-1223.   | 13.2 | 42        |
| 17 | Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia. Cancer Discovery, 2020, 10, 1544-1565.   | 9.4  | 39        |
| 18 | Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. Nature Communications, 2021, 12, 422.   | 12.8 | 36        |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | An <i>In Vivo</i> CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discovery, 2022, 12, 432-449.                                      | 9.4 | 32        |
| 20 | Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. Oncogenesis, 2019, 8, 39.                        | 4.9 | 26        |
| 21 | RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.<br>Leukemia, 2018, 32, 597-605.                                 | 7.2 | 22        |
| 22 | AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia. Cell Reports, 2022, 38, 110197.            | 6.4 | 22        |
| 23 | CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. Oncotarget, 2015, 6, 38061-38078.   | 1.8 | 20        |
| 24 | The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. Leukemia, 2013, 27, 325-335.                        | 7.2 | 17        |
| 25 | Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo.<br>Cancers, 2020, 12, 1725.                                    | 3.7 | 13        |
| 26 | Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3â€ITDâ€driven acute myeloid leukemia. FEBS Open Bio, 2021, 11, 48-60.                       | 2.3 | 4         |
| 27 | AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia. Cancers, 2021, 13, 5966.                | 3.7 | 2         |
| 28 | IDH1 Mutation Enhances Catabolic Flexibility and Mitochondrial Dependencies to Favor Drug<br>Resistance in Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , . | 0.4 | 0         |